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lation tag to a higher degree of cellular proliferation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is well established that the act of self-renewal, particularly
during neuronal differentiation, requires many intrinsic and extrinsic
factors. Neurogenesis and its incorporation into the existing neuronal
circuitry are a central event in the process of efﬁcient aging (Lazarov
et al., 2010). It has been shown that the rate of neurogenesis decreases
as a function of age (Riddle and Lichtenwalner, 2007; Conover and
Shook, 2011), contrary of what has been observed in Alzheimer's
disease (AD) (Jin et al., 2004a, 2004b). Unlike normal aging, the AD
brain is subjected tomany environmental stimulants known to induce
neurogenesis, that is, amyloid (Lopez-Toledano and Shelanski, 2004),
donepezil (Kotani et al., 2008), memantine (Jin et al., 2006),
nonsteroidal anti-inﬂammatory drugs (Monje et al., 2002), brain
trauma (Chen et al., 2003b), and statins (Chen et al., 2003a), to name a
few. Because the environment inside and outside the cell directly
affects epigenetic mechanisms that regulate the expression of multi-
potent genes (Feil and Fraga, 2011; Dao et al., 2014), the increased
multipotency observed in AD (Fitzsimons et al., 2014) implicates
epigenetic mechanisms like 5-hydroxymethylation (Dao et al., 2014).a State University, Tempe, AZ,
Inc. This is an open access article uEpigenetic mechanisms encompass a wide array of functional roles,
which in due course lead to the repression or expression of genes.
Although the existence and biological functions of active methylation
(generally mediating gene repression) and demethylation (generally
inducing gene expression) are still in its infancy, 5hmC has been
implicated in active DNA demethylation (Zhang et al., 2012), particu-
larly in multipotent genes (Szulwach et al., 2011). The
5-hydroxymethylcytosine (5hmeC) mark is an oxidized form of
5-methylcytosine (5meC) (Tahiliani et al., 2009). Oxidation of 5meC
to 5hmeC is catalyzed by a family of proteins (ten-eleven translocation)
that have also been implicated in the regulation and maintenance of
multipotency (Tahiliani et al., 2009; Freudenberg et al., 2012). Because
the subventricular zone (SVZ) is a site of neurogenesis and gliogenesis
(Ming and Song, 2011), our data identify an epigenetic mechanism that
could account for the increase in multipotency observed in AD. These
data provide the foundation for future gene-speciﬁc studies and a
possible therapeutic approach to neuronal differentiation in AD SVZ.
2. Materials and methods
2.1. Autopsy brain tissue
Brain tissue was obtained through the Sun Health Brain and Body
Donation Program (Sun City, AZ). Specimens at autopsy were collected
under institutional review board–approved protocols and informednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of cases used for quantitative assessment
Sex Age expired PMI Control AD Braak score
F 90 3 Yes No II
M 86 2.5 Yes No II
M 86 2.66 Yes No II
F 90 2.5 Yes No II
M 83 2.16 Yes No III
F 96 3 Yes No III
F 86 2.5 No Yes IV
F 91 4.5 No Yes IV
M 85 5.75 No Yes IV
F 85 3.16 No Yes VI
M 79 1.83 No Yes VI
M 86 2.83 No Yes VI
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investigators. At expiration, subject ages ranged from 79 to 96 years old
(N = 12), with amean of 86.9 ± 1.1 (SEM) years. Postmortem intervals
for the subjects averaged 3 hours ± 3 minutes. Diagnoses of patient
condition includedAD (n = 6) andneurologically/pathologically normal
for age (n = 6) (Table 1). Subjects included in this study received
antemortem evaluation by board-certiﬁed neurologists and postmortem
evaluation by a board-certiﬁed neuropathologist. Evaluations and
diagnostic criteria followed consensus guidelines for National Institute
on Aging Alzheimer's Disease Centers.
After brain removal, gross surface neuropathological abnormalities
were documented, 1-cm–thick frontal slabs were cut and photo-
graphed, and the slabs were bisected into hemispheres. Small blocks
that included superior-lateral periventricular white matter were
immediately dissected from right hemisphere slabs and processed
for primary cell culture or for ﬁxation and detailed immunohisto-
chemical study (see below).
2.2. SVZ dissection, tissue dissociation, and primary cell culture
As previously published (Leonard et al., 2009), SVZ cultures were
dissected from the superior lateral wall of the lateral ventricle, from
the most anterior aspect of the lateral ventricle to approximately 3 cm
posterior to that point. These dissections typically included approx-
imately 1 cm of white matter but speciﬁcally excluded any striatal
gray matter. For parallel, control cultures, neocortical tissue blocks
from the same cases were dissected from frontal and/or parietal
regions. These latter slabs always included all adjoining subcortical
white matter, except for a 2-cm margin around the lateral ventricle
that contained the SVZ. Eliminating the SVZ from these samples
provided a control to evaluate whether neurosphere development in
our SVZ cultures derived from the SVZ or from surrounding
periventricular tissue necessarily included in the SVZ dissections.
Tissue was quickly transported in ice-cold Hibernate A medium
(BrainBits, LLC, Springﬁeld, IL) to a sterile laminar ﬂow hood,
mechanically dissociated into 1–2 mm pieces, and digested with
0.25% trypsin (Irvine Scientiﬁc, Santa Ana, CA) and 0.1% DNAse
(Sigma, St. Louis, MO) in a shaking water bath at 30°C. Digestion was
stopped with fetal bovine serum. After passing the cell and tissue
suspension through progressively ﬁner metal screens, it was diluted
with complete Dulbecco modiﬁed Eagle medium (DMEM) (minus
phenol red). CompleteDMEMconsisted of 500mLDMEM(high glucose,
plus or minus phenol red, as noted; Invitrogen-Gibco, Carlsbad, CA), 50
mL fetal bovine serum (Gemini Bio-Products,West Sacramento, CA), 10
mLHEPES (Irvine Scientiﬁc), 5mL sodiumpyruvate (Mediatech Cellgro,
Herndon, VA), 5 mL penicillin/streptomycin (Invitrogen-Gibco), and
0.5 mL gentamycin (Irvine Scientiﬁc). Cells and debris were separated
using 50% Percoll gradient (Amersham/GE Healthcare, Piscataway, NJ)
centrifugation (13,000 rpm; refrigerated). The ﬁrst layer of myelin and
debris was discarded. The second layer of the gradient, which is rich in
microglia and astrocytes (Lue et al., 1996) but also proved to be themostoptimal source for neurospheres, was aspirated, washed, pelleted,
gently triturated, washed a second time, resuspended in complete
DMEM (plus phenol red), and transferred to a 75-mL tissue culture ﬂask
(Nunc, Rochester, NY).
Flasks with suspended cells were left undisturbed for 2–24 hours
in a tissue culture incubator maintained at 37°C/7% CO2. As previously
reported (Lue et al., 1996), some 98% of microglia became adherent
under these conditions, such that culture supernatants that were
relatively free of microglia could be transferred to a second set of
75-mL ﬂasks for plating. To estimate viability and density of the cells
remaining in suspension, 50-μL aliquots of cell suspension were
subjected to trypan blue exclusion counting using a hemocytometer.
The secondaryﬂaskswere left undisturbed, except forweeklymedium
replacement with complete DMEM, for 1–3 weeks in tissue culture
incubators maintained at 37°C with 7% CO2, after which a portion of the
supernatant was seeded into various receptacles depending on experi-
mental requirements. When ﬂasks became conﬂuent, neurospheres and
lightly adherent cell clusters were mechanically dislodged by brief gentle
shaking, gently pelleted and triturated, and plated into a new ﬂask;
neurospheres were not intentionally dissociated during passage. Charac-
terization studies typically used 6- or 12-well uncoated tissue culture
plates (Corning, Lowell, MA) or plates and culture dishes coated with 10
μg/mL poly-L-lysine (Sigma) or a combination of poly-L-lysine /10 μg/mL
mouse laminin I (ATCC, Manassas, VA).
2.3. Immunohistochemistry and immunocytochemistry
For immunohistochemical analysis of tissue sections, periventri-
cular white matter/SVZ blocks were collected at autopsy in the same
manner as that for cell culture. Tissue blocks were immersion-ﬁxed at
4°C for 24–36 hours in freshly made 4% paraformaldehyde/0.1 mol/L
PO4 (phosphate buffer, PB). The blocks were then washed extensively
in PB, cryoprotected in 30% sucrose, sectioned serially at 20 μm or 40
μm on a cryostat, and stored at−20°C in ethylene glycol/glycerol/PB
solution until needed.
2.3.1. 3,3'-diaminobenzidine immunohistochemistry
Forty-micrometer free ﬂoating sections were washed in
phosphate-buffered saline Triton X-100, blocked in 1% hydrogen
peroxide followed by 1-hour incubation in 3% bovine serum albumin
(BSA), and then incubated at 4°C overnight in primary antibody (5hmeC;
Active Motif, Carlsbad, CA; 1:5000 dilution) solutions containing 0.25%
BSA. After incubation, the sections were washed; incubated in biotinyl-
ated, species-speciﬁc secondary antibodies (Vector) for 2 hours at room
temperature (RT); washed 3× in phosphate-buffered saline Triton
X-100; and incubated in avidin-biotin complex (Pierce) for 30 min.
Following incubation with avidin-biotin complex, sections were washed
2× in 50 mmol/L Tris buffer and immersed in 3,3'-diaminobenzidine
solution (500 μL 5 mg/mL 3,3'-diaminobenzidine, 2 mL saturated nickel,
10 μL 1% H202, ﬁll to 50 mL with 50 mmol/L Tris buffer) for no longer
than 10 minutes, followed 2 quick rinses in 50 mmol/L Tris to stop the
reaction. AD and nondiseased (ND) sections were immunoreacted
simultaneously using Netwells in well-less plates. Sections were
mounted with Permount (Pierce).
2.3.2. Fluorescence immunohistochemistry
Brieﬂy, extensively washed 40-μmol/L sections were blocked with
3% normal goat serum (NGS)/0.1% Triton X-100 and then incubated
with rabbit anti-human 5hmeC, diluted 1:5000 (Active Motif,
Carlsbad, CA) for 24 hours at 4°C. The diluent for all solutions and
washes was 0.05 mol/L Tris-buffered saline, pH 7.4. After 3 washes,
the sections were incubated with goat anti-rabbit Alexa-Fluor 488–
conjugated secondary antibody (1:1500; Invitogen/Molecular Probes)
for 2 hours at room temperature, washed, mounted on microscope
slides, and coverslipped with Vectashield mounting medium (Vector
Laboratories, Burlingame, CA). All washes included 1% NGS and 0.1%
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incubation with hydroxymethylated nucleotides (5-hydroxymethyl
dCTP; Zymo Research, Irvine, CA) resulted in abolition of speciﬁc
immunoreactivity. Adjacent serial sections were stained with cresyl
violet for cell layer identiﬁcation and veriﬁcation that the ependymal
layer of the adjacent immunoﬂuorescent sectionswas intact. For some
sections, nuclei were counterstained with 4′,6′-diamidino-2-pheny-
lindole (DAPI; Invitrogen) before mounting.
2.3.3. Fluorescence immunocytochemistry
For immunocytochemical analysis of cell cultures, medium was
aspirated, and cultures were brieﬂy washed with either RT
phosphate-buffered saline (PBS) (Invitrogen-Gibco) or 37°C PEM (100
mmol/L PIPES, 2 mmol/L EGTA, l mmol/L MgSO4, pH 6.9) and then ﬁxed
with RTacetone-ethanol (1:1 for 15 minutes at 4°C). The cells were
washedbrieﬂy, and nonspeciﬁc bindingwasblockedwith either 3%NGS
(Sigma) or 1% BSA (Sigma)/0.1% Triton for 45 minutes at room
temperature. Cultures were then incubated with primary antibody
diluted in 1%NGS/PBS for 1 hour at room temperature. Following 3 brief
washes, cells were incubated with species-appropriate secondary
antibodies conjugated with Alexa-Fluor 488 or Alexa-Fluor 568
ﬂuorophores (Invitrogen/Molecular Probes) for 1 hour at room
temperature in the dark. Washes throughout all steps were with 1×
PBS; as with tissue sections, we observed no speciﬁc immunostaining
when primary antibodies were deleted.
Immunostained periventricular white matter/SVZ tissue sections
and cell cultures were examined on Olympus IX70 microscopes
equippedwith epiﬂuorescence illumination or confocal laser scanning
using argon and krypton lasers (IX70). Findings were documented
photographically with Olympus DP-71 color digital cameras or, for
confocal microscopy, by Fluoview software (Olympus). Contrast and
brightness adjustments and overlay compositing were done with
Adobe Photoshop CS3.
2.4. Slot blot
DNA was isolated from cultured cells using the QIAamp DNA mini
kit (Qiagen) and quantiﬁed using Quant-iT PicoGreen dsDNA Assay
Kit (Life Technologies). One microgram of DNA was denatured using
0.4 mol/L NaOH. Samples were then heated to 100°C for 10 minutes to
ensure complete denaturation. Samples were then neutralized by
adding an equal volume of 2 mol/L ammonium acetate, pH 7.0, to the
target DNA solution. Samples were loaded onto prewet (6× SSC)
Hybond-ECL nitrocellulose membrane loaded into a 48-well Bio-Dot
SF (slot format) microﬁltration unit (Bio-Rad). With the vacuum off,
500 μL of denatured DNA is loaded and pulled through by gravity
ﬁltration, followed by gentle vacuum. Membrane was removed and
allow to air dry for 30 minutes at RT. Once dry, membrane was placed
between 2 pieces of ﬁlter paper and baked under vacuum at 80°C for 2
hours. Membrane was then blocked for 2 hours in 5% milk in dot blot
buffer (20 mmol/L Tris, .05% Tween-20), washed 1× in dot blot buffer,
and incubated in primary antibody (5-hmec, 1:10,000) for 2 hours at
RT in dot blot buffer and 5% milk. Membrane was then washed 5× for
5 minutes and incubated in horseradish peroxidase–conjugated
secondary antibody (anti-rabbit, 1:5000) for 1 hour at RT in dot blot
buffer and 5% milk, followed by 5 washes in dot blot buffer for 5
minutes. Membranes were incubated in ECL reagent and imaged on
AlphaEaseFC (Alpha Innotech). After imaging, membranes were
washed with dH2O and placed in .025% methylene blue for 2 minutes,
washed 1× in dH2O, and imaged on AlphaEaseFC.
2.5. WST-1 assay
Cultured cells from the human SVZwere isolated as described above.
Per manufacturer’s instructions (ABCAM), cells were grown 1 × 104
cells/well in a 96-well microtiter plate in a ﬁnal volume of 100 μL ofcomplete media (described above). After 72 hours, 10 μL of WST-1
reagent was added to each well, including blank wells with no cells
(media and WST-1 reagent only). Cells were incubated in WST-1
reagent for 30minutes in a 37°C incubator and for 1minute on a shaking
platform. Plateswere readusing aWallacmicroplate reader at anoptical
density of 440 nm. All experiments were done in triplicate.2.6. Statistical analyses/quantiﬁcation
Bright ﬁeld/ﬂuorescence intensity analysis was performed using
ImageJ software (ImageJ, US National Institutes of Health, Bethesda,
MD; imagej.nih.gov/ij/). Intensity measurements were corrected for
background differences by dividing the measured intensities with the
average intensity of a background region. Signiﬁcance was deter-
mined using a 2-tailed Student t test and declared signiﬁcant at a P
value b .05.3. Results
3.1. Increased 5-hydroxymethylation immunoreactivity in the SVZ of
Alzheimer's brain in vivo
Quantiﬁcation of 5hmeC immunoreactivity in layer III of the SVZ
showed a signiﬁcant increase in immunoreactivity in AD compared
with age-matched controls (Fig. 1). Layer I (ependymal cell layer), the
innermost cell layer of the SVZ, showed no signiﬁcant difference in
immunoreactivity between AD and ND cases (P = .21; Fig. 1A vs. B).
Similarly, layer II (hypocellular gap), a region which contains little in
the way of cell bodies but does contain astrocytic processes, revealed
no signiﬁcant difference in immunoreactivity between AD and ND
cases (P = .008, Fig. 1A vs. B), although control cases were trending
toward higher 5hmeC levels (Fig. 1A). Analysis of layer III, which
contained multipotent cells, delineated by the presence of GFAP delta
positive immunoreactivity (Leonard et al., 2009), revealed a signiﬁ-
cant increase when comparing AD with control samples (P b .001).
Layer IV, the transition zone between the multipotent astrocytes and
parenchyma, showed no signiﬁcant difference between groups (P =
.19). To enable correction for possible cell loss, the total number of
cells in the SVZ were counted, but no signiﬁcant difference was
observed (P = .22) and therefore no correction was needed.3.2. Quantiﬁcation of 5hmeC immunoreactivity in SVZ, both in vivo
(brain tissue) and in vitro (primary cultures) from matching AD and ND
cases
In vivo data in a case-control study showed signiﬁcantly less
(2-tail, t test P = 4.4e-5) 5hmeC levels (average gray value of pixels,
normalized to cell number intensity DAPI) in the control (Fig. 2, A1)
compared with AD SVZ (Fig. 2, A2). Similarly, primary cultures of the
same individuals show signiﬁcantly less (P = .002) 5hmeC immuno-
reactivity in ND neurospheres (Fig. 2, B1) compared with AD (Fig. 2,
B2). Slot blot analysis of nuclear DNA extracted form neurospheres
and adherent cells from the SVZ revealed a global increase in 5hmeCs
in AD (Fig. 2C–D), in linewith the immunohistochemical experiments.
These data show that both cultured cells and brain tissue from the
same individuals behave similarly with respect to 5hmeC levels.
To determine whether 5 hydroxymethylation levels affect prolifer-
ation potential differentially in AD and ND cultured cells, WST-1
proliferation assays were performed. Fig. 3 shows a signiﬁcant increase
(2-tail, t test P = 2.9 E-07) in the proliferation potential in AD SVZ
precursor cells compared with normal controls. Although correlative,
these data indicate that an increase in 5-hydroxymethylation levels can
predict an increase in proliferation in the SVZ of AD cultured precursor
cells.
Fig. 1. Quantiﬁcation of 5hmeC immunoreactivity in the SVZ of AD (n = 5) and ND (n = 5) brains. Representative photomicrograph analysis of ND SVZ (A) reveals signiﬁcantly less
immunoreactivity in layer III (boxed region) compared with AD cases (B). Bar graphs show the mean intensity for 5hmeC surface area (percentage of area within the delineated
region above background), 2-tail t test, P b .001. Dashed lines indicate the delineated regions for analysis. *Signiﬁcant difference; error bars were generated as standard error of the
mean. LV, left ventricle.
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Stem cells have been proposed to provide the potential to
revolutionize biomedicine in the next 2 decades. New research
already shows that they can replace the lost nerve cells in Parkinson's
disease (Politis and Lindvall, 2012), improve outcomes after heart
attacks (Zakharova et al., 2010), rescue memory in mice with
advanced AD (Yamasaki et al., 2007; Blurton-Jones et al., 2009), and
ameliorate a host of other major human disorders. Although it was
once believed that human stem cells were more or less the exclusive
province of embryos, it is now clear that they persist into adulthood as
adult progenitor stem cells. Indeed, studies conducted by our
laboratory have shown that highly viable, adult progenitors can be
isolated from the SVZ of postmortem brain and retained in culture for
years (Leonard et al., 2009).
Because the SVZ is a site of neurogenesis in the aging brain (Riddle
and Lichtenwalner, 2007) and epigenetic mechanisms have been
implicated in regulating the “normal” distribution of new nerve cells
into the existing cellular milieu (Ma et al., 2010), we tested relative
5hmeC levels in AD because of the critical role 5hmeC has in
mediating the expression of multipotent genes (Navarro et al., 2014).
In the AD SVZ, we determined that there was a signiﬁcant increase in
5hmeC levels in layer III (Fig. 1A) compared with normal controls in
vivo. We further tested 5hmeC levels in vitro in a set of AD and ND
cases and found that both neurospheres and adherent precursor cells
expressed higher levels of 5hmeC levels in AD compared with control.
Finally, we show that this increase in 5hmeC levels correlate to higher
degree of proliferation in culture. Although the sample size is
relatively small, the complimentary data indicate that 5hmeC levelsare consistent in vivo and in vitro, potentially identifying a model for
further analysis.
We further mined the clinical data for an association between
medications taken and a potential increase in cellular proliferation
(data not shown), but no such association was found. This may be due
to the small sample size or the overlap between medication (e.g.,
blood pressure and cholesterol medications) within subjects regard-
less of disease.
Over the past decade, intense investigation within the neurogen-
esis has indicated an increase in cellular proliferation in AD and in AD
mouse models (Jin et al., 2004b; Boekhoorn et al., 2006; Yu et al.,
2009; Mu and Gage, 2011; Perry et al., 2012; Marlatt et al., 2014),
although the relevance of mouse models in recapitulating disease has
been questioned (Kuhn et al., 2007). Although an increase in the
number proliferating cells has been reported in glial, vascular, and
neuronal precursor cells (reviewed in Fitzsimons et al., 2014), none
have identiﬁed a causal mechanism. It has been previously reported
that 5hmeC levels are linked to a higher degree of multipotency and
cellular proliferation (Ficz et al., 2011; Navarro et al., 2014), and here,
we make the case, although speculative, that the increase in
proliferation in AD may be directly linked to the increase in 5hmeC
levels. Undoubtingly, this increase in cellular proliferation would be
advantageous in a disease like AD where neuronal loss is a prominent
pathological feature. However, many of these same reports show that
the number of proliferating cells does not increase in differentiated
neurons in AD (Perry et al., 2012). Although the fact remains that
neurogenesis is an important part of healthy aging, its role in disease
is still unclear. The need for further manipulation studies of the
5hmeC mark, possibly through the actions of ten-eleven translocation
Fig. 2. Quantiﬁcation of 5hmeC immunoreactivity in SVZ both in vivo (brain tissue) and in vitro (neurosphere primary cultures) from matching AD and ND cases. Control SVZ (A1)
shows signiﬁcantly less 5hmeC intensity compared with AD SVZ (A2). Bar graph (A3) shows quantiﬁcation (5hmeC average gray value of pixels, normalized to cell number intensity
DAPI immunoreactivity) of the immunohistochemical results. Similarly, primary cultures of the same individuals show signiﬁcantly less 5hmeC immunoreactivity (P = .002) in ND
neurospheres (B1) compared with AD (B2). Corresponding bar graph (B3) shows quantiﬁcation of the immunocytochemical data. Slot blot analysis of nuclear DNA extracted from
neurospheres and adherent cells from the SVZ reveals a global increase in 5hmeCs in AD (C), slot 1 (AD neurospheres), slot 3 (ND neurospheres), slot 2 (AD adherent cells), and slot 4
(ND adherent cells). Normalized 5hmeC levels to methylene blue signal reveal a signiﬁcant increase in both AD spheres and adherent cells, 2-tail t test, P = .001 and b .001,
respectively (D). *Signiﬁcant difference (P b .05); error bars were generated as standard error of the mean.
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an important cofactor in promoting cellular differentiation. The data
presented here identify a potential model system for further studies in
addressing the epigenetic mechanism(s) to promote cellular
differentiation.Fig. 3.WST-1 proliferation assay. Cultured precursor cells from AD and control brain were pl
salt WST-1 to formazan by cellular mitochondrial dehydrogenases. The reaction yields a col
case vs. control sample. Error bars were generated as standard error of the mean.Acknowledgements
The authors declare no competing ﬁnancial or conﬂict of interests.
We are grateful to the Banner Sun Health Research Institute Brain and
Body Donation Program of Sun City, AZ, for the provision of humanated and incubated in WST-1 reagent, which is based on the cleavage of the tetrazolium
or product indicative of the proliferation rate, which was signiﬁcantly higher in the AD
31D. Mastroeni et al. / Neuroepigenetics 6 (2016) 26–31brain samples. The Brain and Body Donation Program is supported by
the National Institute of Neurological Disorders and Stroke (U24
NS072026 National Brain and Tissue Resource for Parkinson's Disease
and Related Disorders), the National Institute on Aging (P30 AG19610
Arizona Alzheimer's Disease Core Center), the Arizona Department of
Health Services (contract 211002, Arizona Alzheimer's Research
Center), the Arizona Biomedical Research Commission (contracts
4001, 0011, 05-901, and 1001 to the Arizona Parkinson's Disease
Consortium), and the Michael J. Fox Foundation for Parkinson's
Research. This work was supported by NIRG-14-321390 and
ADHS14-080000 FY2015 to DM.References
Blurton-Jones, M., Kitazawa, M., Martinez-Coria, H., Castello, N.A., Muller, F.J., Loring,
J.F., Yamasaki, T.R., Poon, W.W., Green, K.N., LaFerla, F.M., 2009. Neural stem cells
improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl.
Acad. Sci. U. S. A. 106, 13594–13599.
Boekhoorn, K., Joels, M., Lucassen, P.J., 2006. Increased proliferation reﬂects glial and
vascular-associated changes, but not neurogenesis in the presenile Alzheimer
hippocampus. Neurobiol. Dis. 24, 1–14.
Chen, J., Zhang, Z.G., Li, Y., Wang, Y., Wang, L., Jiang, H., Zhang, C., Lu, M., Katakowski, M.,
Feldkamp, C.S., Chopp, M., 2003a. Statins induce angiogenesis, neurogenesis, and
synaptogenesis after stroke. Ann. Neurol. 53, 743–751.
Chen, X.H., Iwata, A., Nonaka, M., Browne, K.D., Smith, D.H., 2003b. Neurogenesis and
glial proliferation persist for at least one year in the subventricular zone following
brain trauma in rats. J. Neurotrauma 20, 623–631.
Conover, J.C., Shook, B.A., 2011. Aging of the subventricular zone neural stem cell niche.
Aging Dis. 2, 149–163.
Dao, T., Cheng, R.Y., Revelo, M.P., Mitzner, W., Tang, W., 2014. Hydroxymethylation as a
novel environmental biosensor. Curr. Environ. Health Rep. 1, 1–10.
Feil, R., Fraga, M.F., 2011. Epigenetics and the environment: emerging patterns and
implications. Nat. Rev. Genet. 13, 97–109.
Ficz, G., Branco, M.R., Seisenberger, S., Santos, F., Krueger, F., Hore, T.A., Marques, C.J.,
Andrews, S., Reik, W., 2011. Dynamic regulation of 5-hydroxymethylcytosine in
mouse ES cells and during differentiation. Nature 473, 398–402.
Fitzsimons, C.P., van Bodegraven, E., Schouten, M., Lardenoije, R., Kompotis, K., Kenis, G.,
van den Hurk, M., Boks, M.P., Biojone, C., Joca, S., Steinbusch, H.W., Lunnon, K.,
Mastroeni, D.F., Mill, J., Lucassen, P.J., Coleman, P.D., van den Hove, D.L., Rutten, B.P.,
2014. Epigenetic regulation of adult neural stem cells: implications for Alzheimer's
disease. Mol. Neurodegener. 9, 9–25.
Freudenberg, J.M., Ghosh, S., Lackford, B.L., Yellaboina, S., Zheng, X., Li, R., Cuddapah, S.,
Wade, P.A., Hu, G., Jothi, R., 2012. Acute depletion of Tet1-dependent 5-
hydroxymethylcytosine levels impairs LIF/Stat3 signaling and results in loss of
embryonic stem cell identity. Nucleic Acids Res. 40, 3364–3377.
Jin, K., Galvan, V., Xie, L., Mao, X.O., Gorostiza OF, Bredesen, D.E., Greenberg, D.A., 2004a.
Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice.
Proc. Natl. Acad. Sci. U. S. A. 101, 13363–13367.
Jin, K., Peel, A.L., Mao, X.O., Xie, L., Cottrell, B.A., Henshall, D.C., Greenberg, D.A., 2004b.
Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U.
S. A. 101, 343–347.
Jin, K., Xie, L., Mao, X.O., Greenberg, D.A., 2006. Alzheimer's disease drugs promote
neurogenesis. Brain Res. 1085, 183–188.Kotani, S., Yamauchi, T., Teramoto, T., Ogura, H., 2008. Donepezil, an acetylcholines-
terase inhibitor, enhances adult hippocampal neurogenesis. Chem. Biol. Interact.
175, 227–230.
Kuhn, H.G., Cooper-Kuhn, C.M., Boekhoorn, K., Lucassen, P.J., 2007. Changes in
neurogenesis in dementia and Alzheimer mouse models: are they functionally
relevant? Eur. Arch. Psychiatry Clin. Neurosci. 257, 281–289.
Lazarov, O., Mattson, M.P., Peterson, D.A., Pimplikar, S.W., van Praag, H., 2010. When
neurogenesis encounters aging and disease. Trends Neurosci. 33, 569–579.
Leonard, B.W., Mastroeni, D., Grover, A., Liu, Q., Yang, K., Gao, M., Wu, J., Pootrakul, D.,
van den Berge, S.A., Hol, E.M., Rogers, J., 2009. Subventricular zone neural
progenitors from rapid brain autopsies of elderly subjects with and without
neurodegenerative disease. J. Comp. Neurol. 515, 269–294.
Lopez-Toledano, M.A., Shelanski, M.L., 2004. Neurogenic effect of beta-amyloid peptide
in the development of neural stem cells. J. Neurosci. 24, 5439–5444.
Lue, L.F., Brachova, L., Walker, D.G., Rogers, J., 1996. Characterization of glial cultures from
rapid autopsies of Alzheimer's and control patients. Neurobiol. Aging 17, 421–429.
Ma, D.K., Marchetto, M.C., Guo, J.U., Ming, G.L., Gage, F.H., Song, H., 2010. Epigenetic
choreographers of neurogenesis in the adult mammalian brain. Nat. Neurosci. 13,
1338–1344.
Marlatt, M.W., Bauer, J., Aronica, E., van Haastert, E.S., Hoozemans, J.J., Joels, M., Lucassen,
P.J., 2014. Proliferation in the Alzheimer hippocampus is due to microglia, not
astroglia, and occurs at sites of amyloid deposition. Neural Plast. 2014 (1-13), 693851.
Ming, G.L., Song, H., 2011. Adult neurogenesis in the mammalian brain: signiﬁcant
answers and signiﬁcant questions. Neuron 70, 687–702.
Monje, M.L., Mizumatsu, S., Fike, J.R., Palmer, T.D., 2002. Irradiation induces neural
precursor-cell dysfunction. Nat. Med. 8, 955–962.
Mu, Y., Gage, F.H., 2011. Adult hippocampal neurogenesis and its role in Alzheimer's
disease. Mol. Neurodegener. 6 (1-9), 85.
Navarro, A., Yin, P., Ono, M., Monsivais, D., Moravek, M.B., Coon, J.S., Dyson, M.T., Wei,
J.J., Bulun, S.E., 2014. 5-hydroxymethylcytosine promotes proliferation of human
uterine leiomyoma: a biological link to a new epigenetic modiﬁcation in benign
tumors. J. Clin. Endocrinol. Metab. 99, E2437–E2445.
Perry, E.K., Johnson, M., Ekonomou, A., Perry, R.H., Ballard, C., Attems, J., 2012. Neurogenic
abnormalities in Alzheimer's disease differ between stages of neurogenesis and are
partly related to cholinergic pathology. Neurobiol. Dis. 47, 155–162.
Politis, M., Lindvall, O., 2012. Clinical application of stem cell therapy in Parkinson's
disease. BMC Med. 10, 1–10.
Riddle, D.R., Lichtenwalner, R.J., 2007. Neurogenesis in the adult and aging brain.
Szulwach, K.E., Li, X., Li, Y., Song, C.X., Han, J.W., Kim, S., Namburi, S., Hermetz, K., Kim,
J.J., Rudd, M.K., Yoon, Y.S., Ren, B., He, C., Jin, P., 2011. Integrating 5-
hydroxymethylcytosine into the epigenomic landscape of human embryonic
stem cells. PLoS Genet. 7, e1002154.
Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S.,
Iyer, L.M., Liu, D.R., Aravind, L., Rao, A., 2009. Conversion of 5-methylcytosine to 5-
hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324,
930–935.
Yamasaki, T.R., Blurton-Jones, M., Morrissette, D.A., Kitazawa, M., Oddo, S., LaFerla, F.M.,
2007. Neural stem cells improve memory in an inducible mouse model of neuronal
loss. J. Neurosci. 27, 11925–11933.
Yu, Y., He, J., Zhang, Y., Luo, H., Zhu, S., Yang, Y., Zhao, T., Wu, J., Huang, Y., Kong, J., Tan,
Q., Li, X.M., 2009. Increased hippocampal neurogenesis in the progressive stage of
Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model.
Hippocampus 19, 1247–1253.
Zakharova, L., Mastroeni, D., Mutlu, N., Molina, M., Goldman, S., Diethrich, E., Gaballa,
M.A., 2010. Transplantation of cardiac progenitor cell sheet onto infarcted heart
promotes cardiogenesis and improves function. Cardiovasc. Res. 87, 40–49.
Zhang, P., Su, L., Wang, Z., Zhang, S., Guan, J., Chen, Y., Yin, Y., Gao, F., Tang, B., Li, Z., 2012.
The involvement of 5-hydroxymethylcytosine in active DNA demethylation in
mice. Biol. Reprod. 86 (1-9), 104.
